XML 55 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Intangible Assets (Details Narrative)
3 Months Ended
Mar. 31, 2022
USD ($)
IPR and D Drug Technology Platforms [Member]  
Restructuring Cost and Reserve [Line Items]  
Asset impairment charges $ 0
IPR and D Drug Technology Platforms [Member] | Ovarian Cancer [Member]  
Restructuring Cost and Reserve [Line Items]  
Finite-lived intangible assets acquired 13,300,000
EGEN Inc [Member]  
Restructuring Cost and Reserve [Line Items]  
Goodwill 2,000,000.0
EGEN Inc [Member] | Purchase Agreement [Member]  
Restructuring Cost and Reserve [Line Items]  
Finite-lived intangible assets acquired $ 1,600,000
Finite-lived intangible asset, useful life 7 years
Amortization $ 56,829
EGEN Inc [Member] | Glioblastoma Multiforme Brain Cancer [Member]  
Restructuring Cost and Reserve [Line Items]  
Asset impairment charges 2,000,000.0
Non-cash charge 2,000,000.0
EGEN Inc [Member] | IPR and D Drug Technology Platforms [Member]  
Restructuring Cost and Reserve [Line Items]  
Indefinite-lived intangible assets acquired $ 24,200,000